Cardiometabolic & kidneyMeta-analysis
Association Between Clonal Hematopoiesis and Cardiometabolic Disease
- Systematic review and meta-analysis of observational studies
- random-effects models
- Risk of bias assessed with the Newcastle-Ottawa Scale
Authors' conclusion
CH is associated with cardiometabolic outcomes and may exhibit heterogeneity across mutations and clinical phenotypes, supporting its role as a somatic genomic marker of cardiometabolic risk.
Study context
- Population
- Adults in observational studies reporting age-adjusted associations between clonal hematopoiesis (CH) and cardiometabolic outcomes18 studies · >650,000 individuals
- Comparison
- CH vs no CH
- Outcome
- Primary outcomes (HRs from random-effects models)
Pooled result
As reported in the abstract
CH vs No CHHazard ratio (95% CI)
MI
1.14(1.00–1.29)
stroke
1.12(1.03–1.23)
CV mortality
1.20(1.07–1.36)
T2DM
1.20(1.02–1.41)
Further pooled results
| Outcome | HR (95% CI) | |
|---|---|---|
| Driver gene analyses — TET2 mutations vs No CH · stroke | 1.41 (1.03–1.93) | |
| Driver gene analyses — ASXL1 mutations vs No CH · CV mortality | 2.22 (1.37–3.60) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Association Between Clonal Hematopoiesis and Cardiometabolic Disease. JACC CardioOncol. doi:10.1016/j.jaccao.2026.04.005
Summarised from the published abstract; every number is checked against it